Fibrati (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fibrati" in Italian language version.

refsWebsite

Global rank Italian rank

24doi.org

2^nd place

7^th place

21nih.gov

4^th place

9^th place

19oadoi.org

799^th place

22^nd place

3archive.org

6^th place

8^th place

2fda.gov

447^th place

644^th place

2archive.is

87^th place

low place

1espacenet.com

800^th place

1,504^th place

1web.archive.org

1^st place

1europa.eu

68^th place

57^th place

1agenziafarmaco.gov.it

low place

1,603^rd place

1jlr.org

low place

1freepatentsonline.com

5,449^th place

6,476^th place

1jbc.org

4,455^th place

2,750^th place

1hematologylibrary.org

low place

1stacommunications.com

low place

agenziafarmaco.gov.it

Determinazione 6 giugno 2011 (allegato 1) (PDF), su Gazzetta Ufficiale, vol. 163, Agenzia italiana del farmaco, 15 luglio 2011. URL consultato l'11 settembre 2011.

archive.is

Laurence Brunton, Bruce Chabner; Bjorn Knollman, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12ª ed., McGraw-Hill Professional, 17 dicembre 2010, p. 1808, ISBN 978-0-07-162442-8. URL consultato il 15 luglio 2023 (archiviato dall'url originale il 6 marzo 2013).
«became the most widely prescribed hypolipidemic drug.»
Barter PJ, Rye KA, Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?, in Circulation, vol. 113, n. 12, marzo 2006, pp. 1553–5, DOI:10.1161/CIRCULATIONAHA.105.620450, PMID 16567579. URL consultato il 15 luglio 2023 (archiviato dall'url originale il 14 aprile 2013).

archive.org

R. Arakawa, N. Tamehiro; T. Nishimaki-Mogami; K. Ueda; S. Yokoyama, Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner., in Arterioscler Thromb Vasc Biol, vol. 25, n. 6, Jun 2005, pp. 1193-7, DOI:10.1161/01.ATV.0000163844.07815.c4, PMID 15790930.
JP. Guichard, P. Blouquin; Y. Qing, A new formulation of fenofibrate: suprabioavailable tablets., in Curr Med Res Opin, vol. 16, n. 2, 2000, pp. 134-8, PMID 10893657.
JT. Backman, C. Kyrklund; M. Neuvonen; PJ. Neuvonen, Gemfibrozil greatly increases plasma concentrations of cerivastatin., in Clin Pharmacol Ther, vol. 72, n. 6, Dec 2002, pp. 685-91, DOI:10.1067/mcp.2002.128469, PMID 12496749.

doi.org

dx.doi.org

J. M. Thorp, W. S. Waring, Modification of Metabolism and Distribution of Lipids by Ethyl Chlorophenoxyisobutyrate, in Nature, vol. 194, n. 4832, 1962, pp. 948–949, DOI:10.1038/194948a0. URL consultato il 9 settembre 2012.
J.M. Thorp, Experimental evaluation of an orally active combination of androsterone with ethyl chlorphenoxyisobutyrate, in The Lancet, vol. 279, n. 7243, 1962, pp. 1323–1326, DOI:10.1016/S0140-6736(62)92423-6. URL consultato il 9 settembre 2012.
M.F. Oliver, Reduction of serum-lipid and uric-acid levels by an orally active androsterone, in The Lancet, vol. 279, n. 7243, 1962, pp. 1321–1323, DOI:10.1016/S0140-6736(62)92422-4. URL consultato il 9 settembre 2012.
WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators., in Lancet, vol. 2, n. 8403, settembre 1984, pp. 600-4, DOI:10.1016/S0140-6736(84)90595-6, PMID 6147641.
KennethG. Green, M.F. Oliver, J.A. Heady, J.N. Morris, J. Cooper, Interpretation of clofibrate trial, in The Lancet, vol. 324, n. 8411, 1984, pp. 1095–1096, DOI:10.1016/S0140-6736(84)91531-9. URL consultato il 9 settembre 2012.
M. C. Bateson, D. Maclean, P. E. Ross, Ian A. D. Bouchier, Clofibrate therapy and gallstone induction, in The American Journal of Digestive Diseases, vol. 23, n. 7, 1978, pp. 623–628, DOI:10.1007/BF01072597. URL consultato il 9 settembre 2012.
Gareth F. Blane, Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, in The American Journal of Medicine, vol. 83, n. 5, 1987, pp. 26–36, DOI:10.1016/0002-9343(87)90868-0, PMID 3318450. URL consultato il 9 settembre 2012.
M. Heikki Frick, Olli Elo, Kauko Haapa, Olli P. Heinonen, Pertti Heinsalmi, Pekka Helo, Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia, in New England Journal of Medicine, vol. 317, n. 20, 1987, pp. 1237–1245, DOI:10.1056/NEJM198711123172001, PMID 3313041. URL consultato il 9 settembre 2012.
Hanna Bloomfield Rubins, Sander J. Robins, Dorothea Collins, Carol L. Fye, James W. Anderson, Marshall B. Elam, Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol, in New England Journal of Medicine, vol. 341, n. 6, 1999, pp. 410–418, DOI:10.1056/NEJM199908053410604. URL consultato il 9 settembre 2012.
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, in The Lancet, vol. 375, n. 9729, 2010, pp. 1875–1884, DOI:10.1016/S0140-6736(10)60656-3. URL consultato il 9 settembre 2012.
Bart Staels, Fibrates in CVD: a step towards personalised medicine, in The Lancet, vol. 375, n. 9729, 2010, pp. 1847–1848, DOI:10.1016/S0140-6736(10)60758-1. URL consultato il 30 settembre 2012.
Steiner G, Atherosclerosis in type 2 diabetes: a role for fibrate therapy?, in Diab Vasc Dis Res, vol. 4, n. 4, dicembre 2007, pp. 368–74, DOI:10.3132/dvdr.2007.067, PMID 18158710.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ, Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review, in Am J Med, vol. 122, 2009, pp. 962.e1-962.e8, DOI:10.1016/j.amjmed.2009.03.030, PMID 19698935.
B. Idzior-Walus, J. Sieradzki; W. Rostworowski; A. Zdzienicka; E. Kawalec; J. Wójcik; A. Zarnecki; G. Blane, Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X., in Eur J Clin Invest, vol. 30, n. 10, ottobre 2000, pp. 871-8, DOI:10.1046/j.1365-2362.2000.00734.x, PMID 11029601.
R. Arakawa, N. Tamehiro; T. Nishimaki-Mogami; K. Ueda; S. Yokoyama, Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner., in Arterioscler Thromb Vasc Biol, vol. 25, n. 6, Jun 2005, pp. 1193-7, DOI:10.1161/01.ATV.0000163844.07815.c4, PMID 15790930.
Anthony R. Godfrey, Jennifer DiGiacinto, Matthew W. Davis, Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials, in Clinical Therapeutics, vol. 33, n. 6, 2011, pp. 766–775, DOI:10.1016/j.clinthera.2011.05.047. URL consultato il 12 settembre 2012.
H. B. Matthews, S. Kato, The metabolism and disposition of halogenated aromatics, in Annals of the New York Academy of Sciences, vol. 320, 1 Health Effect, 1979, pp. 131–137, DOI:10.1111/j.1749-6632.1979.tb56596.x. URL consultato l'11 settembre 2012.
Isabelle Issemann, Stephen Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, in Nature, vol. 347, n. 6294, 1990, pp. 645–650, DOI:10.1038/347645a0. URL consultato il 12 settembre 2012.
Y. Guan, Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome., in J Am Soc Nephrol, vol. 15, n. 11, Nov 2004, pp. 2801-15, DOI:10.1097/01.ASN.0000139067.83419.46, PMID 15504933.
K. Motojima, Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor alpha and gamma Activators in a Tissue- and Inducer-specific Manner (PDF), in Journal of Biological Chemistry, vol. 273, n. 27, 1998, pp. 16710–16714, DOI:10.1074/jbc.273.27.16710. URL consultato il 12 settembre 2012.
Barter PJ, Rye KA, Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?, in Circulation, vol. 113, n. 12, marzo 2006, pp. 1553–5, DOI:10.1161/CIRCULATIONAHA.105.620450, PMID 16567579. URL consultato il 15 luglio 2023 (archiviato dall'url originale il 14 aprile 2013).
A Hanafy, H Spahnlangguth, G Vergnault, P Grenier, M Tubicgrozdanis, T Lenhardt, Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug☆, in Advanced Drug Delivery Reviews, vol. 59, n. 6, 2007, pp. 419–426, DOI:10.1016/j.addr.2007.04.005. URL consultato il 12 settembre 2012.
PH. Guivarc'h, MG. Vachon; D. Fordyce, A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions., in Clin Ther, vol. 26, n. 9, Sep 2004, pp. 1456-69, DOI:10.1016/j.clinthera.2004.09.015, PMID 15531008.
JT. Backman, C. Kyrklund; M. Neuvonen; PJ. Neuvonen, Gemfibrozil greatly increases plasma concentrations of cerivastatin., in Clin Pharmacol Ther, vol. 72, n. 6, Dec 2002, pp. 685-91, DOI:10.1067/mcp.2002.128469, PMID 12496749.

espacenet.com

worldwide.espacenet.com

Brevetto GB 860303

europa.eu

ema.europa.eu

(EN) Questions and answers on the review of medicines containing fibrates (PDF), su ema.europa.eu, Agenzia europea per i medicinali, ottobre 2010. URL consultato l'11 settembre 2011.

fda.gov

accessdata.fda.gov

(EN) ATROMID-S, su Drugs@FDA, Food and Drug Administration. URL consultato il 9 settembre 2012.
(EN) MEVACOR, su Drugs@FDA, Food and Drug Administration. URL consultato il 9 settembre 2012.

freepatentsonline.com

Pharmaceutical composition and method for treatment of digestive disorders - Patent 4976970, su freepatentsonline.com. URL consultato il 20 dicembre 2008.

hematologylibrary.org

bloodjournal.hematologylibrary.org

M. Kockx, PP. Gervois; P. Poulain; B. Derudas; JM. Peters; FJ. Gonzalez; HM. Princen; T. Kooistra; B. Staels, Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. (PDF) ^{[collegamento interrotto]}, in Blood, vol. 93, n. 9, maggio 1999, pp. 2991-8, PMID 10216095.

jbc.org

K. Motojima, Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor alpha and gamma Activators in a Tissue- and Inducer-specific Manner (PDF), in Journal of Biological Chemistry, vol. 273, n. 27, 1998, pp. 16710–16714, DOI:10.1074/jbc.273.27.16710. URL consultato il 12 settembre 2012.

jlr.org

K. Schoonjans, B. Staels; J. Auwerx, Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. (PDF), in J Lipid Res, vol. 37, n. 5, maggio 1996, pp. 907-25, PMID 8725145.

nih.gov

ncbi.nlm.nih.gov

DK. Wysowski, DL. Kennedy; TP. Gross, Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988., in JAMA, vol. 263, n. 16, aprile 1990, pp. 2185-8, PMID 2319684.
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators (PDF), in Br Heart J., vol. 40, n. 10, ottobre 1978, pp. 1069–1118. URL consultato il 9 settembre 2012.
WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators., in Lancet, vol. 2, n. 8403, settembre 1984, pp. 600-4, DOI:10.1016/S0140-6736(84)90595-6, PMID 6147641.
DA. Hussar, New drugs of 1998., in J Am Pharm Assoc (Wash), vol. 39, n. 2, pp. 151-206; quiz 289-92, PMID 10079651.
Gareth F. Blane, Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, in The American Journal of Medicine, vol. 83, n. 5, 1987, pp. 26–36, DOI:10.1016/0002-9343(87)90868-0, PMID 3318450. URL consultato il 9 settembre 2012.
M. Heikki Frick, Olli Elo, Kauko Haapa, Olli P. Heinonen, Pertti Heinsalmi, Pekka Helo, Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia, in New England Journal of Medicine, vol. 317, n. 20, 1987, pp. 1237–1245, DOI:10.1056/NEJM198711123172001, PMID 3313041. URL consultato il 9 settembre 2012.
Steiner G, Atherosclerosis in type 2 diabetes: a role for fibrate therapy?, in Diab Vasc Dis Res, vol. 4, n. 4, dicembre 2007, pp. 368–74, DOI:10.3132/dvdr.2007.067, PMID 18158710.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ, Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review, in Am J Med, vol. 122, 2009, pp. 962.e1-962.e8, DOI:10.1016/j.amjmed.2009.03.030, PMID 19698935.
B. Idzior-Walus, J. Sieradzki; W. Rostworowski; A. Zdzienicka; E. Kawalec; J. Wójcik; A. Zarnecki; G. Blane, Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X., in Eur J Clin Invest, vol. 30, n. 10, ottobre 2000, pp. 871-8, DOI:10.1046/j.1365-2362.2000.00734.x, PMID 11029601.
R. Arakawa, N. Tamehiro; T. Nishimaki-Mogami; K. Ueda; S. Yokoyama, Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner., in Arterioscler Thromb Vasc Biol, vol. 25, n. 6, Jun 2005, pp. 1193-7, DOI:10.1161/01.ATV.0000163844.07815.c4, PMID 15790930.
K. Schoonjans, B. Staels; J. Auwerx, Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. (PDF), in J Lipid Res, vol. 37, n. 5, maggio 1996, pp. 907-25, PMID 8725145.
Y. Guan, Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome., in J Am Soc Nephrol, vol. 15, n. 11, Nov 2004, pp. 2801-15, DOI:10.1097/01.ASN.0000139067.83419.46, PMID 15504933.
N. Latruffe, M. Cherkaoui Malki; V. Nicolas-Frances; MC. Clemencet; B. Jannin; JP. Berlot, Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases., in Biochem Pharmacol, vol. 60, n. 8, Oct 2000, pp. 1027-32, PMID 11007938.
M. Kockx, PP. Gervois; P. Poulain; B. Derudas; JM. Peters; FJ. Gonzalez; HM. Princen; T. Kooistra; B. Staels, Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. (PDF) ^{[collegamento interrotto]}, in Blood, vol. 93, n. 9, maggio 1999, pp. 2991-8, PMID 10216095.
Barter PJ, Rye KA, Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?, in Circulation, vol. 113, n. 12, marzo 2006, pp. 1553–5, DOI:10.1161/CIRCULATIONAHA.105.620450, PMID 16567579. URL consultato il 15 luglio 2023 (archiviato dall'url originale il 14 aprile 2013).
JP. Guichard, P. Blouquin; Y. Qing, A new formulation of fenofibrate: suprabioavailable tablets., in Curr Med Res Opin, vol. 16, n. 2, 2000, pp. 134-8, PMID 10893657.
PH. Guivarc'h, MG. Vachon; D. Fordyce, A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions., in Clin Ther, vol. 26, n. 9, Sep 2004, pp. 1456-69, DOI:10.1016/j.clinthera.2004.09.015, PMID 15531008.
HY. Yun, E. Joo Lee; S. Youn Chung; SO. Choi; H. Kee Kim; JT. Kwon; W. Kang; KI. Kwon, The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule., in Clin Pharmacokinet, vol. 45, n. 4, 2006, pp. 425-32, PMID 16584288.
R. Sauron, M. Wilkins; V. Jessent; A. Dubois; C. Maillot; A. Weil, Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation., in Int J Clin Pharmacol Ther, vol. 44, n. 2, Feb 2006, pp. 64-70, PMID 16502765.
JT. Backman, C. Kyrklund; M. Neuvonen; PJ. Neuvonen, Gemfibrozil greatly increases plasma concentrations of cerivastatin., in Clin Pharmacol Ther, vol. 72, n. 6, Dec 2002, pp. 685-91, DOI:10.1067/mcp.2002.128469, PMID 12496749.
JS. Wang, M. Neuvonen; X. Wen; JT. Backman; PJ. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes., in Drug Metab Dispos, vol. 30, n. 12, Dec 2002, pp. 1352-6, PMID 12433802.

oadoi.org

J. M. Thorp, W. S. Waring, Modification of Metabolism and Distribution of Lipids by Ethyl Chlorophenoxyisobutyrate, in Nature, vol. 194, n. 4832, 1962, pp. 948–949, DOI:10.1038/194948a0. URL consultato il 9 settembre 2012.
J.M. Thorp, Experimental evaluation of an orally active combination of androsterone with ethyl chlorphenoxyisobutyrate, in The Lancet, vol. 279, n. 7243, 1962, pp. 1323–1326, DOI:10.1016/S0140-6736(62)92423-6. URL consultato il 9 settembre 2012.
M.F. Oliver, Reduction of serum-lipid and uric-acid levels by an orally active androsterone, in The Lancet, vol. 279, n. 7243, 1962, pp. 1321–1323, DOI:10.1016/S0140-6736(62)92422-4. URL consultato il 9 settembre 2012.
WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators., in Lancet, vol. 2, n. 8403, settembre 1984, pp. 600-4, DOI:10.1016/S0140-6736(84)90595-6, PMID 6147641.
KennethG. Green, M.F. Oliver, J.A. Heady, J.N. Morris, J. Cooper, Interpretation of clofibrate trial, in The Lancet, vol. 324, n. 8411, 1984, pp. 1095–1096, DOI:10.1016/S0140-6736(84)91531-9. URL consultato il 9 settembre 2012.
M. C. Bateson, D. Maclean, P. E. Ross, Ian A. D. Bouchier, Clofibrate therapy and gallstone induction, in The American Journal of Digestive Diseases, vol. 23, n. 7, 1978, pp. 623–628, DOI:10.1007/BF01072597. URL consultato il 9 settembre 2012.
Gareth F. Blane, Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, in The American Journal of Medicine, vol. 83, n. 5, 1987, pp. 26–36, DOI:10.1016/0002-9343(87)90868-0, PMID 3318450. URL consultato il 9 settembre 2012.
M. Heikki Frick, Olli Elo, Kauko Haapa, Olli P. Heinonen, Pertti Heinsalmi, Pekka Helo, Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia, in New England Journal of Medicine, vol. 317, n. 20, 1987, pp. 1237–1245, DOI:10.1056/NEJM198711123172001, PMID 3313041. URL consultato il 9 settembre 2012.
Hanna Bloomfield Rubins, Sander J. Robins, Dorothea Collins, Carol L. Fye, James W. Anderson, Marshall B. Elam, Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol, in New England Journal of Medicine, vol. 341, n. 6, 1999, pp. 410–418, DOI:10.1056/NEJM199908053410604. URL consultato il 9 settembre 2012.
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, in The Lancet, vol. 375, n. 9729, 2010, pp. 1875–1884, DOI:10.1016/S0140-6736(10)60656-3. URL consultato il 9 settembre 2012.
Bart Staels, Fibrates in CVD: a step towards personalised medicine, in The Lancet, vol. 375, n. 9729, 2010, pp. 1847–1848, DOI:10.1016/S0140-6736(10)60758-1. URL consultato il 30 settembre 2012.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ, Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review, in Am J Med, vol. 122, 2009, pp. 962.e1-962.e8, DOI:10.1016/j.amjmed.2009.03.030, PMID 19698935.
B. Idzior-Walus, J. Sieradzki; W. Rostworowski; A. Zdzienicka; E. Kawalec; J. Wójcik; A. Zarnecki; G. Blane, Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X., in Eur J Clin Invest, vol. 30, n. 10, ottobre 2000, pp. 871-8, DOI:10.1046/j.1365-2362.2000.00734.x, PMID 11029601.
Anthony R. Godfrey, Jennifer DiGiacinto, Matthew W. Davis, Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials, in Clinical Therapeutics, vol. 33, n. 6, 2011, pp. 766–775, DOI:10.1016/j.clinthera.2011.05.047. URL consultato il 12 settembre 2012.
H. B. Matthews, S. Kato, The metabolism and disposition of halogenated aromatics, in Annals of the New York Academy of Sciences, vol. 320, 1 Health Effect, 1979, pp. 131–137, DOI:10.1111/j.1749-6632.1979.tb56596.x. URL consultato l'11 settembre 2012.
Isabelle Issemann, Stephen Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, in Nature, vol. 347, n. 6294, 1990, pp. 645–650, DOI:10.1038/347645a0. URL consultato il 12 settembre 2012.
Y. Guan, Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome., in J Am Soc Nephrol, vol. 15, n. 11, Nov 2004, pp. 2801-15, DOI:10.1097/01.ASN.0000139067.83419.46, PMID 15504933.
A Hanafy, H Spahnlangguth, G Vergnault, P Grenier, M Tubicgrozdanis, T Lenhardt, Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug☆, in Advanced Drug Delivery Reviews, vol. 59, n. 6, 2007, pp. 419–426, DOI:10.1016/j.addr.2007.04.005. URL consultato il 12 settembre 2012.
PH. Guivarc'h, MG. Vachon; D. Fordyce, A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions., in Clin Ther, vol. 26, n. 9, Sep 2004, pp. 1456-69, DOI:10.1016/j.clinthera.2004.09.015, PMID 15531008.

stacommunications.com

Fibrates inPerspective - Answering an Age-Old Question

web.archive.org

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: design, methods and progress (PDF), in Bull Wld Hlth. Org., vol. 408, n. 2, 1973, pp. 243–256. URL consultato il 9 settembre 2012 (archiviato dall'url originale il 7 novembre 2005).